On May 23, 2018, Health Canada published Overview of the Reporting Adverse Reactions to Marketed Health Products - Guidance Document for Industry. “This guidance document provides market authorization holders (MAHs) with assistance on how to comply with the Food and Drugs Act, the Food and Drug Regulations and the Natural Health Products Regulations with respect to reporting adverse reactions (ARs) to marketed health products”, including: pharmaceutical drugs, biologics, radiopharmaceutical drugs and natural health products. These ARs are to be reported to the Canada Vigilance Program of the Marketed Health Products Directorate (MHPD) of Health Canada.
Related Publications & Articles
-
Agile licensing amendments registered
Following consultation starting in 2022, on November 29, 2024, Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) were registered.Read More -
2024 highlights in Canadian life sciences IP and regulatory law
In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
Health Canada proposes to amend the Food and Drug Regulations and Medical Devices Regulations to address shortages
On December 28, 2024, Health Canada published proposed amendments to the Food and Drug Regulations and Medical Devices Regulations to address therapeutic product shortages (see our previous article re...Read More